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Introduction: The aim of this prospective, observational, multi-
center study was to examine the epidemiology and management
costs of bone metastatic disease (BMD) in patients with lung cancer.
Methods: The analysis included all patients with BMD from lung
cancer diagnosed between May 2006 and May 2007 in 40 centers.
We analyzed their management and the direct costs of BMD from
the health care provider’s perspective, using a Markov model.
Skeletal-related event (SRE) was defined as pathological fractures,
spinal cord compression, or hypercalcemia (clinical SRE [cSRE])
for an initial analysis; a second analysis included palliative radio-
therapy and surgery (therapeutic SRE [tSRE]).
Results: Among the 554 patients enrolled (62  11 years, 76.5%
males, 69.3% performance status 0/1, 91% non-small cell lung
cancer), 24.7% had a cSRE and 26.7% a tSRE at baseline and 9%
and 39% during follow-up, respectively; 81.8% received at least one
chemotherapy cycle. The median survival time was 5.8 months, and
the 1- and 2-year survival rates were 22% and 7%, respectively;
there was no significant difference in overall survival between the
patients with and without SRE at enrollment. The main BMD
treatments were opiate therapy (77.7%), biphosphonates (52.3%),
radiotherapy (42.1%), and surgery (9.2%). The mean monthly BMD
treatment costs in euros were €190, €374, and €4672 for asymptom-
atic patients, symptomatic patients, and patients with SRE, respec-
tively. The average first-year BMD management cost in euros was
€3999  4135 (95% confidence interval: 374–15,886), and 49.5%
of this cost was attributable to patients with SRE.
Conclusions: This analysis confirms the poor prognosis of BMD
from lung cancer and underlines the burden of SRE in overall
treatment costs.
Key Words: Bone metastases, Non-small cell lung cancer, Costs,
Biphosphonates, Zoledronic acid.
(J Thorac Oncol. 2011;6: 576–582)
The number of patients diagnosed with advanced-stagelung cancer is expected to increase in coming years, and,
even though the prognosis remains dismal, median survival is
also increasing as new treatments are developed. Given the
limitations of current therapeutic options, palliation of symp-
toms due to metastatic disease remains a primary concern. In
particular, bone metastases occur in 30 to 65% of patients
with lung cancer,1 and most patients with bone metastatic
disease (BMD) experience skeletal-related events (SREs;
clinical SRE [cSRE]), defined as pathological fractures, spi-
nal cord compression, or hypercalcemia. Such complications
frequently require bone irradiation, opiate analgesics for
severe pain, and surgery to correct fractures or spinal defor-
mities.2 SRE can occur regardless of the radiographic appear-
ance of bone lesions. In a recent clinical trial, most patients
with BMD from non-small cell lung cancer (NSCLC) expe-
rienced SRE during the first 5 months of the study.3 These
events result in impaired mobility and quality of life, have a
significant negative impact on survival, and are associated
with increased health care costs.4–9 Nevertheless, despite the
importance of this problem, there are no prospective epide-
miological studies of the characteristics and natural history of
patients with lung cancer with BMD. Biphosphonates and
especially intravenous zoledronic acid, have been shown in a
double-blinded randomized trial to reduce the incidence of
SRE in patients with solid tumors.3,7,10–12 Other new treat-
ments are being developed. For example, denosumab, which
specifically targets the receptor activator of nuclear factor
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kappa B ligand, a key osteoclast regulatory factor, is being
studied for its potential to delay the onset of BMD and to
inhibit and treat bone destruction in patients with advanced-
stage lung cancer.2,13 The cost-effectiveness of these treat-
ments is poorly established.14–16 The objective of this pro-
spective, observational, multicenter study was to document
the epidemiology, management, and BMD treatment costs of
patients with lung cancer with BMD.
MATERIALS AND METHODS
The study involved all patients aged at least 18 years
who were managed in 1 of the 40 participating centers for
histologically or cytologically proven lung cancer and a
diagnosis of bone metastasis between May 1, 2006, and May
1, 2007. The patients were enrolled prospectively to this
purely observational study, and the investigators were asked
to provide 1 month of follow-up information retrospectively
to avoid the risk of modifying usual practices. Regardless of
symptoms, bone metastasis had to be confirmed either by
standard radiography and technetium 99 bone scintigraphy,
or by computed tomography or magnetic resonance imaging.
Concurrent bone disease (i.e., Paget’s disease or myeloma)
was an exclusion criterion. The analysis focused on sociode-
mographic characteristics, lung cancer characteristics, BMD
characteristics (diagnosis, location, and management), and
laboratory findings. Monthly follow-up visits focused on the
course of bone metastases and especially SRE, SRE manage-
ment, and related health care consumption. SRE was defined
as pathological fractures, spinal cord compression, or hyper-
calcemia (cSRE) for the initial analysis, then a second anal-
ysis included palliative radiotherapy or surgery for BMD in
the definition (therapeutic SRE [tSRE]). Follow-up lasted for
12 months after BMD diagnosis or until death.
We used a Markov approach (implemented with deci-
sion analysis software from TreeAge, Williamstown, MA) to
model first-year management costs in this cohort of patients
with lung cancer with BMD. We distinguished the different
management phases, both for each patient and for each
1-month period (patients were classified by two of the au-
thors—C.D. and C.C.). The simulation was run as shown in
Figure 1. After initial diagnosis of BMD, each patient is in
one of the following four exhaustive and mutually exclu-
sive health states: asymptomatic bone metastasis (ABM);
symptomatic bone disease (SBM; escalation of specific
treatment for more than 3 days); SRE, acute bone-related
event (at least one SRE, defined as a fracture, vertebral
compression, spinal compression, or acute hypercalcemia);
and death (absorbent state).
Between each monthly clinical assessment, each patient
is in one of the four following health states: ABM, SBM,
SRE, or death. In the next cycle, the cohort was partitioned
among the four states, resulting in a new distribution. Base-
line probabilities and probabilities of transition from one
health state to another over time were established by analyz-
ing the management modalities of the study cohort. We used
a Markov model to analyze the expected monetary cost of
BMD management. Confidence intervals (95%) were ob-
tained by Monte-Carlo simulation.
Economic Valorization
The economic analysis adopted the health care payer’s
perspective and took into account only direct costs (i.e.,
consumption of health care resources). Indirect costs (e.g.,
lost income) and intangible costs (e.g., pain and suffering)
were not assessed. Hospitalization costs (administration, se-
curity, maintenance, general equipment, central supply, die-
tetics, and social services) were assessed on a per diem basis
(national unit cost scale for each event) for fixed costs and
from drug purchase prices in the establishments concerned.17
Medical costs (nursing, care, ward supplies, pharmacy, diag-
nostic tests, laboratory tests, and professional services) were
determined by chart review. Transport costs were estimated
from the national scale. A mean monthly cost was calculated
for each of the four health states.
Statistical Analysis
Quantitative variables are expressed as means and SD and
were compared with one way analysis of variance, Student’s t
test, or the Mann-Whitney U test depending on the variable.
Qualitative variables are expressed as numbers and percentages
and were compared with the 2 test or Fisher’s exact test.
Significance was assumed at p less than 0.05. Overall
survival rates were estimated with the Kaplan-Meier method,
and groups were compared using the log-rank test. The Cox
model was used to identify factors predictive of survival.
FIGURE 1. Median survival of pa-
tients with and without skeletal-re-
lated events defined as pathological
fractures, spinal cord compression,
or hypercalcemia (cSRE).
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Multivariate logistic regression analysis was used to identify
baseline variables with independent predictive value for SRE.
The study was approved by the Limoges University
Hospital ethics committee on March 4, 2006. The sponsors
had no role in the study design, study realization, data
analysis, or manuscript preparation. Groupe Français de
Pneumo-Cancérologie (GFPC) is the proprietor of the results.
The data were analyzed and interpreted by the authors.
RESULTS
Five hundred fifty-four patients were enrolled in the 40
centers between May 2006 and May 2007. Mean age was 62
11 years, and 76.5% of the patients were men. The patients were
in good general condition (performance status [PS], 0/1) in
69.3% of cases. The lung cancer was NSCLC in 91% of cases
(Table 1). BMD was diagnosed before, at the same time, or after
lung cancer in 151 (27.3%), 72 (13%), and 331 (59.7%) cases,
respectively. In this last case, BMD was diagnosed a mean of
192  336 days after lung cancer. The diagnosis was based on
technetium scintigraphy in 62.2% of cases (Table 2) and on
positron emission tomography scan, computed tomography
scan, or magnetic resonance imaging in the others cases. The
mean metastatic bone sites at BMD diagnosis was 3.6 3.5; the
most frequent locations being the spine (56.3%), ribs (38.1%),
and pelvis (30.1%). At baseline, BMD was revealed by 93 cSRE
in 87 patients. During follow-up, 73 new cSRE occurred in 73
patients, of whom 23 had already had a cSRE (Table 2). The
analysis of tSREs showed that 148 patients (26.7%) had a tSRE
at baseline and that 234 tSREs occurred during follow-up
(62.2% and 35% of patients with and without tSREs at inclusion,
respectively). There is no significant difference of incidence of
cSRE when we compare patients with PS 0/1 and patients with
PS more than 1 (13.8% and 20% at inclusion, p  0.064, and
25% and 24.1% during follow-up, respectively).
After BMD diagnosis, 453 (81.8%) patients received at
least one cycle of chemotherapy (88.8% for PS 0/1 patients,
65.9% for patients with PS 1, p  0.001). Table 3 lists the
specific treatments received for BMD. Most patients received
analgesics (mainly opiates). Slightly more than half of the
patients (52.3%) received biphosphonates, usually by the
intravenous route, every 3 or 4 weeks (zoledronic acid, 4 mg),
TABLE 1. Patient Characteristics
Characteristics n  554
Gender (male/female) 76.5%/23.5%
Age (yr, mean  SD) 62  11
Performance status
0/1 384 (69.3%)
2/3/4 170 (30.7%)
Histology
NSCLC 498 (91%)
Adenocarcinoma/squamous/others 57.8%/15.3%/17.9%
SCLC 49 (9%)
Metastases others than bone 350 (64.6%)
Liver/lung/brain/adrenals/others 23.9%/33.9%/18.2%/19.9%/8.2%
Prior lung cancer treatments
None 361 (65.2%)
Chemotherapy/radiotherapy/surgery 193 (34.8%)
NSCLC, non-small cell lung cancer; SCLC, small cell lung cancer.
TABLE 2. Characteristics of Bone Metastasis Disease (BMD)
Characteristics of Bone Metastasis
Disease (BMD) n  554
Time between lung cancer diagnosis and BMD
(n, mean  SD days)
BMD before lung cancer diagnosis 151 (27.3%), 14.4  17
Simultaneous diagnosis of BM and lung
cancer
72 (13%)
BM after lung cancer diagnosis 331 (59.7%), 192  336
Diagnostic modalities
Standard radiography 15 (2.7%)
Technetium scintigraphy 347 (62.2%)
TEP-CT and/or CT and/or MRI 192 (35.1%)
Number of bone metastasis sites at diagnosis
(mean  SD)
3.6  3.5
Types of SRE at diagnosis
Hypercalcemia 37
Pathological fracture 27
Vertebral collapse 13
Spinal compression 16
Radiotherapy or surgery 148
Types of SRE during follow-up
Hypercalcemia 14
Pathological fracture 31
Vertebral collapse 7
Spinal compression 21
Radiotherapy or surgery 234
Biological values (mean  SD)
Calcemia (mmol/liter), n  429 2.31  0.2
Corrected calcemia (mmol/liter), n  173 2.40  0.2
Alkaline phosphatase (IU/liter), n  419 166  167
Proteinemia (g/liter), n  412 67  8
Albuminemia (g/liter), n  412 34  7
Creatinemia (mol/liter), n  500 81.1  56.86
Creatinine clearance (ml/min), n  450 88.4  58
50 ml/min 57 (12.5%)
SRE, skeletal-related event; MRI, magnetic resonance imaging; CT, computed
tomography; TEP, positron emission tomography.
TABLE 3. Treatments for Bone Metastatic Disease
Management N  554
Analgesicsa 498 (89.9%)
Nonopioid therapy 111 (22.3%)
Opioid therapy 387 (77.7%)
Biphosphonates 290 (52.3%)
IV 279 (96.2%)
Oral 11 (3.8%)
Radiotherapy 233 (42.1%)
Surgery 51 (9.2%)
a Patients are classified according to the highest level of analgesics received during
the study.
IV, intravenous.
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and usually combined with chemotherapy. The presence of
cSREs at inclusion did not influence biphosphonate prescrip-
tion. In contrast, patients who experienced cSRE during
follow-up were more likely to receive biphosphonates (65.8%
versus 43.5%, p  0.001). There was no correlation between
biphosphonate prescription and the onset of cSREs.
The median survival time was 5.8 months, and the 1-
and 2-year survival rates were 22% and 7%, respectively.
There was a significant difference in overall survival between
patients with PS 0/1 and patients with PS more than 1 (6.9
versus 3.1 months, p  0.001). No difference was noted
according to whether BDM was diagnosed before or after the
diagnosis of cancer. Factors predictive of survival were
adenocarcinoma (p  0.005 versus other histological types,
hazard ratio [HR]: 0.75 [0.62–0.92]), PS 0/1 (p  0.001
versus PS 1, HR: 0.52 [0.42–0.64]), and female sex (p 
0.001 versus men, HR: 0.62 [0.49–0.80]). There was no
significant difference in survival between patients with and
without cSRE (median survival time, 5.3 and 6 months,
respectively, Figure 1); in contrast, there was a significant
difference between patients with and without tSREs (6.6
versus 4.7 months, p  0.02, Figure 2). Factors predictive of
cSRE during follow-up, in both univariate and multivariate
analysis, were a history of SRE at enrollment and PS 0/1
FIGURE 2. Median survival of pa-
tients with and without skeletal-re-
lated events defined as pathological
fractures, spinal cord compression,
hypercalcemia, radiotherapy, or sur-
gery (tSRE).
TABLE 4. Factors Predictive of Skeletal-Related Events Defined as Pathological Fractures, Spinal Cord Compression, or
Hypercalcemia (cSRE) during Follow-Up: Univariate and Multivariate Analysis
SRE, n  73
No SRE,
n  477
Univariate Analysis, OR,
95% CI, p
Multivariate Analysis, OR,
95% CI, p
Age, mean (SD) 60.3 (11.34) 62.3 (10.95) 0.983 (0.961–1.006), p  0.1455 NA
Gender
Male (ref.) 54 (12.9%) 366 (87.1%)
Female 19 (14.6%) 111 (85.4%) 1.160 (0.660–2.040), p  0.6058 NA
Performance status
0/1 (ref.) 59 (15.5%) 322 (84.5%)
2/3/4 14 (8.3%) 155 (91.7%) 0.493 (0.267–0.910), p  0.0238 0.448 (0.239–0.842), p  0.0126
SRE at enrollment
Yes (ref.) 23 (26.7%) 63 (73.3%)
No 50 (10.8%) 414 (89.2%) 0.331 (0.189–0.579), p  0.0001 0.317 (0.177–0.565), p  0.0001
Chemotherapy
No (ref.) 11 (11.3%) 86 (88.7%)
Yes 62 (13.7%) 391 (86.3%) 1.240 (0.627–2.453), p  0.5372 NA
Histological type
Squamous (ref.) 7 (8.4%) 76 (91.6%)
No squamous 65 (14.1%) 396 (85.9%) 1.782 (0.787–4.036), p  0.1659 NA
CI, confidence interval; NA, not applicable.
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(Table 4). BMD-specific health care consumption is summa-
rized in Table 5. Fifty-one patients made 111 hospitalizations
in outpatient clinics (for pain control and biphosphonate
administration), 159 were hospitalized on 239 occasions for
an average of 21  18 days, mainly for surgery, hypercalce-
mia, pain control, or complications of BMD, and eight pa-
tients were hospitalized at home, on one occasion each, for a
mean of 20  11 days, for complications of BMD. The total
cost of BMD in the entire cohort was €1,715,213 (Table 5).
The monthly cost of the ABM, SBM, and SRE health states
was €190, €374, and €4672, respectively. The Markov model
showed that the mean BMD management cost during the first
year after BMD onset was €3999  4135 (95% confidence
interval: 374–15,886), of which 49.5% was linked to man-
agement of patients with SRE and 38.9% and 11.6% to
management of symptomatic patients without SRE and
asymptomatic patients, respectively.
DISCUSSION
This prospective multicenter cohort study confirms the
gravity of BMD in patients with lung cancer, with a median
overall survival time of 5.8 months and 1- and 2-year survival
rates of 22% and 7%, respectively. A recent prospective
study8 of 118 patients gave slightly better results, with a
median survival time of 7.2 months and 1- and 2-year overall
survival rates of 31.6% and 11.3%, respectively. Better out-
come was associated with female sex, adenocarcinoma, PS
1, solitary bone metastases, no metastases of appendicular
bone, no pathologic fractures, and systemic chemotherapy.
Only the first three factors (female gender, adenocarcinoma,
and PS 0/1) were also predictive of survival in our study. SRE
is a major complication of MBD, but the correlation with
poorer survival observed in several studies was confirmed in
this study only when we included radiotherapy and surgery in
the definition of SRE. Indeed, to better take into account
disparities in practices across the participating centers, we
first analyzed SREs without radiotherapy (cSRE) then with
radiotherapy (tSRE). The use of radiotherapy in this setting
depends on national practices, the existence of pain manage-
ment teams, and the availability of radiotherapy facilities and
staff. A higher incidence of SREs was found in patients with
good PS, probably because of their greater longevity. Nev-
ertheless, when we added radiotherapy to the definition of
SREs, PS was no longer predictive of tSRE.
In a recent 2-year biphosphonate trial, among patients
with BMD from NSCLC, most patients in the placebo group
experienced a SRE during the first 5 months.3 In our study,
the median survival time after SRE was 5.3 months, in
keeping with the results of Delea et al.,4,5 who found that
patients with NSCLC survived for a median of approximately
4 months after experiencing their first SRE.
Only 50% of our patients received biphosphonates,
with no significant difference between patients with and
without SRE. Nevertheless, the benefits of these drugs in
patients with lung cancer with BMD have been shown in
recent studies.3
Zoledronic acid is approved for use in patients with any
solid tumor, based on the results of a randomized, placebo-
controlled phase III trial, in which patients with BMD from
solid tumors other than breast or prostate cancer received
zoledronic acid or a placebo.3 Among the 507 patients ran-
domized in this trial, 249 had NSCLC and 36 had small cell
lung cancer. In the overall trial population, zoledronic acid
significantly reduced the proportion of patients who experi-
enced at least one SRE relative to the placebo (39% versus
48%; p  0.039), reduced the proportion of patients who
experienced each type of SRE, significantly reduced the
annual incidence of SRE, and significantly delayed the me-
dian time to a first SRE. Preexisting skeletal morbidity does
not preclude the benefits of subsequent therapy. Indeed,
patients who have already experienced an SRE are at an
especially high risk of subsequent events. This was also the
case in our study, a first SRE being associated with an
increased risk of a second SRE. The efficacy of biphospho-
nates for primary and/or secondary SRE prevention is also
confirmed by observational studies. A retrospective claim-
based analysis15 compared the outcomes of breast, lung, and
prostate cancer in 4546 patients receiving (n  1508) or not
receiving (n  3038) zoledronic acid. Patients on zoledronic
acid were younger, had fewer comorbidities, and had longer
follow-up. Zoledronic acid was associated with a 33% reduc-
tion in the monthly risk of SRE and delayed the onset of a
second SRE.
The costs of BMD in patients with lung cancer had
been analyzed in several recent reports.4,5 MBD is a signifi-
cant driver of oncology costs. In a retrospective registry-
based study,22 the mean direct medical cost of patients with
MBD (all cancers) was $75,329, when compared with
$31,382 in controls (patients with cancer but without BMD).
SREs are also associated with increased health care costs. In
a retrospective analysis of a large U.S. health insurance
claims database of 534 patients with lung cancer and BMD,
TABLE 5. Consumption of Bone Metastasis Disease-Specific
Health Care
Care Quantity Cost (€2009)
Hospitalizations (number)
Outpatient care 111 115,731
Conventional hospitalization 238 472,430
Home hospitalization 8 7431
Total 595,592
Analgesics (months of treatment)
Step 1 210 3150
Step 2 480 26,353
Step 3 1905 223,136
Total 252,639
Biphosphonates (months of treatment)
IV 775 304,923
Oral 89 20,599
Total 325,522
Radiotherapy (patients treatments) 233 305,136
Medical transport 1405 236,324
Total costs 1,715,213
IV, intravenous.
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including 295 (55%) with at least one SRE, the acute man-
agement cost for an SRE was $11,979 (2004 value). Radio-
therapy accounted for 61% of this cost. In our study, 49.5%
of BMD first-year management costs were linked to manage-
ment of patients with cSREs. It should be stressed that,
despite the short survival in this setting, BDM has an impor-
tant economic impact.
Most cost-effectiveness analyses in this setting have
focused on breast cancer.14,18–20 An exhaustive economic/
scientific impact analysis of reports and the literature (1966–
2001) concluded that biphosphonates were likely to be cost-
effective in patients with breast cancer with skeletal
morbidity and in those with secondary BMD and that they
might be cost-effective when fracture care and/or other vari-
ables are considered.4 A cost-utility analysis14 of pamidronate
prevention of SRE in the same population of patients with
advanced-stage breast cancer, adopting the Canadian health
care system perspective, showed an incremental cost-effec-
tiveness of $18,700 per quality-adjusted life-year. The results
of the sensitivity analysis suggested that this estimate was
dependent on the cost of treating SRE events.
Our study has certain limitations. First, we studied only
patients with preexisting BMD, and cannot, therefore, spec-
ulate on primary prevention of BMD. The cost analysis did
not take into account indirect costs that are probably an
important part of total costs, especially in case of SRE. In
addition, a cost-efficacy analysis focused on quality-adjusted
life-year would greatly strengthen our results, but we found
no published data on utilities for the different health states of
BMD disease in lung cancer.
In conclusion, this study confirms the poor prognosis of
patients with lung cancer with bone metastases and shows the
importance of SRE in the specific costs of BMD manage-
ment. Further prospective studies are needed to determine the
cost-effectiveness of different drug-based strategies for pre-
venting BMD and SRE in patients with lung cancer.
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